5-Amino-1MQ and SLU-PP-332 Together: What Is Known
5-Amino-1MQ and SLU-PP-332 taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
Side by side
Showing 5 of 11 fields where the two differ. Category, FDA status, PCAC vote, Jul 2026, WADA, Half-life, Evidence strength are the same or both unknown.
| Field | 5-Amino-1MQ | SLU-PP-332 |
|---|---|---|
| Class | NNMT inhibitor (not a peptide) | ERR agonist (not a peptide) |
| Also called | 5-amino, 1MQ | slupp, SLU-PP |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | Not FDA approved · research chemical | Not FDA approved · research chemical |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | WADA status unclear5-Amino-1MQ is not named. S4.4 covers AMPK activators, PPAR-delta agonists and Rev-erb agonists by example, and nothing there names an NNMT inhibitor. This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance. | WADA status unclearSLU-PP-332 is not named. S4.4 lists AMPK activators, PPAR-delta agonists and Rev-erb agonists; SLU-PP-332 is an ERR agonist, which the list does not mention. This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance. |
| Half-life | No published half-life foundPubMed search, 11 Oct 2026 | No published half-life foundPubMed search, 11 Oct 2026 |
| Evidence strength | Animal evidence, 2 of 4Strongest: Scientific reports 2022, PMID 35013352 | Animal evidence, 2 of 4Strongest: The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806 |
| Human studies we summarised | 0 human (0 randomized or controlled) of 4 summarised | 0 human (0 randomized or controlled) of 7 summarised |
| Typical study doses |
| Not reported in study abstractsPubMed search, 11 Oct 2026 |
| Vial sizes sold | 5 mg, 10 mg | 5 mg |
5-Amino-1MQ vs SLU-PP-332
Choosing between the two rather than combining them? The comparison lines them up field by field.
Two lab compounds with different targets
5-amino-1MQ is a quinolinium inhibitor of the enzyme NNMT; in obese mice it was paired with a low-fat diet and normalised adiposity.[2]
SLU-PP-332 is an ERR agonist that mimicked exercise-induced benefits on whole-body metabolism in mice.[6]
Together, and in people
A PubMed title and abstract search on 2 Oct 2026 for 5-amino-1MQ with SLU-PP-332 returned 0 records.
Calculated from pubmed query ("5-amino-1MQ"[tiab] OR 5-amino-1-methylquinolinium[tiab]) AND ("SLU-PP-332"[tiab]); search date 2026-10-02; records returned 0; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key 5-amino-1mq__slu-pp-332); no arithmetic applied.
For SLU-PP-332, a systematic review of mouse and cell models states that clinical trials are needed to confirm efficacy and safety in humans.[12]
Status
The Drugs@FDA lookup for SLU-PP-332 returned no match.[13]
The same lookup for 5-amino-1MQ returned no match.[14]
A study of SLU-PP-332 metabolites states that WADA prohibits exercise mimetics, and that identifying metabolites is a step toward detecting misuse.[15]
Common questions
5-amino-1MQ vs SLU-PP-332: what is the difference?
One blocks an enzyme (NNMT), the other activates ERR receptors; both have only mouse or cell data in the sources reviewed.[6]
Can you stack 5-amino-1MQ and SLU-PP-332?
The dataset search found no record of the two being tested together, and a systematic review says clinical trials are needed for SLU-PP-332.[12]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.Scientific reports · 2022PMID 35013352Accessed 2 Oct 2026
- 3Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2021PMID 33645410Accessed 2 Oct 2026
- 4PubMed search: "5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab] (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: nicotinamide N-methyltransferase[tiab] AND (quinolinium[tiab] OR 5-amino-1MQ[tiab] OR "5-amino-1-methylquinolinium"[tiab] OR 5MQ[tiab]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6A Synthetic ERR Agonist Alleviates Metabolic Syndrome.The Journal of pharmacology and experimental therapeutics · 2024PMID 37739806Accessed 2 Oct 2026
- 7PubMed search: "SLU-PP-332"[tiab] (10 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: SLU-PP-332[tiab] OR SLU-PP-915[tiab] OR "ERR agonist"[tiab] AND exercise mimetic[tiab] (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("5-amino-1MQ"[tiab] OR 5-amino-1-methylquinolinium[tiab]) AND ("SLU-PP-332"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("5-amino-1MQ"[tiab] OR "5-amino-1-methylquinolinium"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (0 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 11PubMed search: ("SLU-PP-332"[tiab] OR "SLU-PP-915"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 12[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications].Revista medica de Chile · 2026PMID 42024694Accessed 2 Oct 2026
- 13Drugs@FDA (openFDA) search: active ingredient "SLU-PP-332"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 14Drugs@FDA (openFDA) search: active ingredient "5-amino-1MQ"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 15Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.Drug testing and analysis · 2026PMID 41688415Accessed 2 Oct 2026
Found an error? Report a correction.